scholarly journals Under the dynamic environment of normal diagnosis and treatment in the bronchoscope room, the study of the removal efficiency of the new air purifier on microbial aerosols

2021 ◽  
Author(s):  
Lijuan Wu ◽  
XIXIN YAN
Keyword(s):  
Removal Efficiency ◽  
Dynamic Environment ◽  
Diagnosis And Treatment ◽  
Microbial Culture ◽  
Test Results ◽  
Microbiological Test ◽  
Purification Efficiency ◽  
Filtration Membrane ◽  
Air Purifier ◽  
Generation Sequencing

Abstract Background The SARS-CoV-2 can spread through droplets, aerosols, etc. In the case of a severe outbreak of the SARS-CoV-2, the use of new air purifiers in work and living places has a certain effect on reducing the spread of the SARS-CoV-2. There are abundant microbial aerosols in the indoor medical environment. The innovation of this experiment lies in the use of long-term, large-volume sampling methods under the multi-factor dynamic conditions of normal diagnosis and treatment in the bronchoscope room, and the use of two microbial detection methods at the same time to study the removal efficiency of the new air purifier on microbial aerosols ; The innovation of the new air purifier lies in outdoor fresh air and steady-state displacement flow technology. Methods In this experiment, the test group and the control group were set up. Gelatin filtration membrane and PTFE filtration membrane were used to sample the microbial aerosols in the bronchoscope room. Long time (39.5h) and large sampling volume (70590L) was used. A total of 16 days of pure working time sampling was carried out for a period of 1 month. The collected specimens were tested by two methods: next-generation sequencing (mNGS) and microbial culture identification. The researcher retrieved and recorded the microbiological test results of related patients, and compared them with the results of this experiment. Results The result of next-generation sequencing (mNGS): The total purification efficiency was 88.0%. Microbial culture counting and identification results: the total purification efficiency is 87.5%. The results are statistically significant. There is a certain correlation between the experimental results and the clinical microbiological test results of patients. Conclusions 1. The new type of air purifier has a good effect on the removal of microbial aerosols in the bronchoscope room; 2. A variety of microorganisms involved in the experiment can be transmitted through aerosols. Discussion The new air purifier has a total removal efficiency of more than 85% of microorganisms under the dynamic environment of the hospital's normal diagnosis and treatment, and the purification efficiency of a single microorganism ranges 50%-100%. Such removal efficiency may have a positive effect for the control of the SARS-CoV-2 epidemic.

scholarly journals Next-Generation Sequencing in Tumor Diagnosis and Treatment

Diagnostics ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 962
Author(s):  
Dario de Biase ◽  
Matteo Fassan ◽  
Umberto Malapelle
Keyword(s):  
Next Generation Sequencing ◽  
Tumor Diagnosis ◽  
Diagnosis And Treatment ◽  
Next Generation ◽  
Multiple Genes ◽  
Next Generation Sequencing Ngs ◽  
Very High ◽  
Generation Sequencing ◽  
High Depth

Next-Generation Sequencing (NGS) allows for the sequencing of multiple genes at a very high depth of coverage [...]

scholarly journals Colorectal Cancer Biomarkers in the Era of Personalized Medicine

2019 ◽  
Vol 9 (1) ◽  
pp. 3 ◽  
Author(s):  
Jai Patel ◽  
Mei Fong ◽  
Megan Jagosky
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Therapy Response ◽  
Dose Intensity ◽  
Cancer Biomarkers ◽  
Clinical Implications ◽  
Test Results ◽  
First Line ◽  
Genomic Markers ◽  
Generation Sequencing

The 5-year survival probability for patients with metastatic colorectal cancer has not drastically changed over the last several years, nor has the backbone chemotherapy in first-line disease. Nevertheless, newer targeted therapies and immunotherapies have been approved primarily in the refractory setting, which appears to benefit a small proportion of patients. Until recently, rat sarcoma (RAS) mutations remained the only genomic biomarker to assist with therapy selection in metastatic colorectal cancer. Next generation sequencing has unveiled many more potentially powerful predictive genomic markers of therapy response. Importantly, there are also clinical and physiologic predictive or prognostic biomarkers, such as tumor sidedness. Variations in germline pharmacogenomic biomarkers have demonstrated usefulness in determining response or risk of toxicity, which can be critical in defining dose intensity. This review outlines such biomarkers and summarizes their clinical implications on the treatment of colorectal cancer. It is critical that clinicians understand which biomarkers are clinically validated for use in practice and how to act on such test results.

The Removal of Impurity Silicon from Aluminum Melt by the Addition of K2TiF6

2017 ◽  
Vol 748 ◽  
pp. 192-196 ◽  
Author(s):  
Guo Liang Zhu ◽  
Rui Wang ◽  
Wei Wang ◽  
Da Shu ◽  
An Ping Dong ◽  
...  
Keyword(s):  
Removal Efficiency ◽  
Silicon Concentration ◽  
Aluminum Melt ◽  
Purification Efficiency ◽  
Initial Silicon ◽  
Novel Method ◽  
Holding Temperature

A novel method to remove impurity silicon from aluminum melt by the addition of K2TiF6 was studied. The mechanism for silicon removal is the formation and sedimentation of Ti(Al1-x,Six)3 phase and the removal efficiency is mostly decided by the solubility of silicon in TiAl3 phase, which increases with the increasing of the initial silicon concentration in aluminum melt. The effect of holding temperature on the impurity Si purification efficiency was investigated and the result indicated that the effect of holding temperature is very finite.

scholarly journals Acute myelitis after SARS-CoV-2 infection: a case report

2020 ◽  
Author(s):  
Kang Zhao ◽  
Jucun Huang ◽  
Dan Dai ◽  
Yuwei Feng ◽  
Liming Liu ◽  
...  
Keyword(s):  
Acute Flaccid Paralysis ◽  
Clinical Findings ◽  
Lower Limbs ◽  
Nasopharyngeal Swab ◽  
Comprehensive Treatment ◽  
Nucleic Acid Testing ◽  
Test Results ◽  
Microbiological Test ◽  
Novel Coronavirus ◽  
Post Infectious

AbstractWe report a case of acute myelitis in a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A 66-year-old man with coronavirus disease 2019 was admitted with acute flaccid paralysis of the bilateral lower limbs and urinary and bowel incontinence. All serum microbiological test results were negative, except for SARS-CoV-2 nucleic acid testing. Clinical findings indicated post-infectious acute myelitis. He received treatment containing ganciclovir, lopinavir/ritonavir, moxifloxacin, dexamethasone, human immunoglobulin, and mecobalamin. With a diagnosis of post-infectious acute myelitis and comprehensive treatment, paralysis of the bilateral lower extremities ameliorated. After two negative novel coronavirus RNA nasopharyngeal swab tests, he was discharged and transferred to a designated hospital for isolation and rehabilitation therapy.

scholarly journals Analysis of Clinical Characteristics of 19 Patients with Endophthalmitis Caused by Liver Abscess

2021 ◽  
Author(s):  
guangsen liu ◽  
Yue Li ◽  
Wei Wang ◽  
Lei Gao
Keyword(s):  
Visual Acuity ◽  
Liver Abscess ◽  
Diagnosis And Treatment ◽  
Endogenous Endophthalmitis ◽  
Klebsiella Pneumonia ◽  
Microbial Culture ◽  
Poor Vision ◽  
Ocular Symptoms ◽  
History Of ◽  
First Time

Abstract Objective: To analyze the clinical features, treatment, and prognosis of endophthalmitis caused by a liver abscess.Methods: All cases of endogenous endophthalmitis caused by a liver abscess in our hospital in the past 7 years were analyzed retrospectively. The data collected included age, sex, history of diabetes, initial and final vision, pathogen, course of the disease, treatment, and prognosis.Results: 21 eyes of 19 patients were complicated with liver abscess. The average age was 55.9 ±9.8 years old, including 10 males (52.6%) and 9 females (44.4%), 13 patients complicated with diabetes (71.4%), 14 patients (66.7%) first went to the ophthalmology department for diagnosis and treatment and 5 with hepatobiliary surgery (33.3%). 14 patients had a fever before onset, with an average fever time of 5.8 days. Before treatment, the duration of ocular symptoms was 7.71 ±6.68 days, 5.71 ±1.25 days for patients who go to ophthalmology for diagnosis and treatment for the first time, and 12.2 ±3.58 days for patients who go to other departments. After treatment, the average visual acuity of 21 eyes was 0.013, and the average best-corrected visual acuity was 0.79. In the 21 eyes, vitreous fluid culture was positive in 7 eyes (33.3%), all of which were Klebsiella pneumonia. Among the 14 patients with fever during hospitalization, 5 cases were positive for blood microbial culture, all of which were Klebsiella pneumonia. After vitrectomy, the average visual acuity was improved by 4.90 ±2.47 letters and that of patients without vitrectomy was-0.25±0.16letters. The visual acuity of patients who underwent postoperative visual was significantly better than that of patients without postoperative visual (P＜0.096). The visual acuity of patients without vitrectomy was significantly higher than that of patients without vitrectomy (P ＜0.01). 3 eyes (33.3%) of 9 eyes in the IVI group were removed because of uncontrolled inflammation, and 1 eye of 12 eyes in the PPV group was removed because of inflammation recurrence.Conclusion: The prognosis of endogenous endophthalmitis caused by liver abscess is generally poor, but early treatment can save part of the vision. The first visit non-ophthalmology department will delay the early diagnosis of the disease. Diabetes is an important risk factor for endogenous endophthalmitis and poor vision in patients with liver abscess. Klebsiella pneumonia is the main pathogen of intraocular infection. Vitrectomy combined with vitreous injection of antibiotics can improve the prognosis. A systematic and thorough treatment of a liver abscess is of great significance to prevent the recurrence of endophthalmitis in a liver abscess.

scholarly journals Advancing Healthcare Outcomes for Sickle Cell Disease in Nigeria Using Mobile Health Tools

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2173-2173
Author(s):  
Arwa Fraiwan ◽  
Muhammad Noman Hasan ◽  
Ran An ◽  
Amy J. Rezac ◽  
Nicholas J. Kocmich ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Mobile Health ◽  
Sub Saharan Africa ◽  
Diagnosis And Treatment ◽  
Test Results ◽  
Cell Disease ◽  
The World ◽  
Equity Ownership ◽  
Sub Saharan

Nigeria leads the world in the number of cases of sickle cell disease (SCD). An estimated 150,000 babies are born annually in Nigeria with SCD, a heredity disorder, and 70-90% die before age 5. Only a small portion of affected infants and children in sub Saharan Africa (SSA) reach adolescence. Over 650 children die per day in sub-Saharan Africa from SCD. These dismal statistics are in sharp contrast to outcomes in high-income countries (HICs) where more than 90% of SCD patients reach adulthood. The World Health Organization (WHO) estimates that 70% of deaths could be prevented with a low cost diagnostic and treatment plan. Meaningful preventive care and treatment cannot be implemented without a structured plan for early diagnosis and patient tracking.Early diagnosis requires improved access to parents and guardians of children with SCD, and gaining this access remains a challenge in most of SSA. In 2015, Nigeria's Kano state government, with support from foreign partners, established a community-based program for newborn registration. This platform provides unique access to newborn babies in one of Nigeria's most populous cities, but still lacks a functioning patient testing, tracking, and monitoring system, which we plan to address in our ongoing study. This study will introduce mobile health in a low-income country with low literacy rate and hopefully accustom that segment of the population to more varied mobile health applications that will ultimately improve their health in the long run. Our current operational platform in Kano, Nigeria provides access to a large population with a high prevalence of SCD. We have previously completed pilot testing of 315 subjects for SCD using our microchip electrophoresis test. We are planning to test up to 4,500 additional subjects less than 5 years of age at Murtala Muhammed Specialist Hospital. The hospital staff includes 97 physicians and 415 nurses and outpatient clinics serve about 30,000 patients monthly. The maternity department has a 200-bed capacity and the antenatal clinic performs about 1,000 deliveries and serves an average of 3,000 mothers monthly. Enrollment is planned to start on September 15, 2019 and medical staff are currently being trained to run the tests. Our study is registered in the United States National Library of Medicine's ClinicalTrials.gov (Identifier: NCT03948516). Our technology is uniquely paired with an automatic reader and an Electronic Medical Record (EMR) and patient management solution to record POC test results, register new cases, and track patients for follow-up (Fig. 1). The reader enables automated interpretation of test results, local and remote test data storage, and includes geolocation (Global Positioning System) (Fig. 2). The system will generate reports for all cases of SCD, track hospital visits, appointments, lab tests, and will have mobile and dashboard applications for tracking patients and samples. The application will be installed on mobile devices provided to users. The proposed system will be compliant with the existing privacy standards to handle medical data (e.g., HIPAA in the US and GDPR in the EU). All communications between the parties will be secured via end-to-end encryption as a safeguard. We anticipate that our project will increase the rates of screening, diagnosis and timely treatment of SCD in Kano State of Nigeria. The project's broader impact will likely be the ability to track and monitor screening, disease detection, diagnosis and treatment, which can be scaled up to the whole nation of Nigeria, then to sub-Saharan Africa. The data obtained and analyzed will be the first of their kind and will be used to inform the design of programs to improve access to, and availability of, effective care for this underserved populations. The importance of increased access to diagnosis and treatment should not be underestimated - it is crucial for realizing effective management of people with SCD. The impact can be enhanced by complementing diagnosis and patient tracking with education for the families so they can provide or seek the necessary preventative treatment. Identification of the location of the patients in need would help identify the areas where family, parent, caregiver education should be provided. Disclosures Fraiwan: Hemex Health, Inc.: Equity Ownership, Patents & Royalties. Hasan:Hemex Health, Inc.: Equity Ownership, Patents & Royalties. An:Hemex Health, Inc.: Patents & Royalties. Thota:Hemex Health, Inc.: Employment. Gurkan:Hemex Health, Inc.: Consultancy, Employment, Equity Ownership, Patents & Royalties, Research Funding.

Transformer + GAN based Traditional Chinese Medicine inpatient prescription recommendation (Preprint)

2021 ◽  
Author(s):  
Hong Zhang
Keyword(s):  
Decision Making ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Electronic Medical Records ◽  
Clinical Diagnosis ◽  
Medical Records ◽  
Training Data ◽  
Diagnosis And Treatment ◽  
Test Results ◽  
Treatment Scheme

BACKGROUND Clinical diagnosis and treatment decision making support is at the core of medical artificial intelligent research, in which Traditional Chinese Medicine (TCM) decision making is an important part. Traditional Chinese Medicine is a traditional medical system originated from China, of which the main clinical model is to conduct individualized diagnosis and treatment by relying on the four-diagnosis information. One of the key tasks of the TCM artificial intelligence research is to develop techniques and methods of clinical prescription decision making which takes all the relevant information of a patient as input, and produces a diagnosis and treatment scheme as output. Given the complexity of TCM clinical diagnosis and treatment schemes, decision making support of clinical diagnosis and treatment schemes remains as a research challenge for lacking of an effective solution. Fortunately, as the volume of the massive clinical data in the form of electronic medical records increases rapidly, it becomes possible for the computer to produce personalized diagnosis and treatment scheme recommendation through machine learning on the basis of the clinical big data. OBJECTIVE The objective of this research is to develop a real-time diagnosis and treatment scheme recommendation model for TCM inpatients. This is accomplished by using historical clinical medical records as training data to train a Transformer network. Furthermore, to alleviate the issue of overfitting, a Generative Adversarial Network is used to generate noise-added samples from the original training data. These noise-added samples along with the original samples form the complete train data set. METHODS valid information, such as the patient’s current sickness situation, medicines taken, nursing care given, vital signs, examinations and test results, is extracted from the patient’s electronic medical records, then the obtained information is sorted chronically, to produce a sequence of data of each patient. These time-sequence data is then used as input to the Transformer network. The output of the network would be the prescription information a physician would give. Overfitting is a common problem in machine learning, and becomes especially server when the network is complex with insufficient training data. In this research, a Generative Adversarial Network, is used to double the number of training samples by producing noise-added samples from the original samples. This, to a great extent, lessens the overfitting problem. RESULTS A total of 21,295 copies of inpatient electronic medical records from Guang’anmen traditional Chinese medicine hospital was used in this research. These records were created between January 2017 and December 2018, covering a total of 6352 kinds of medicines. These medicines were sorted into 829 types of first category medicines based on the class relationships among medicines. As shown by the test results, the performance of a fully trained Transformer model can have an average precision rate of 80.58%，and an average recall rate of 68.49%. CONCLUSIONS As shown by the preliminary test results, the Transformer-based TCM prescription recommendation model outperforms the existing conventional methods. The extra training samples generated by the GAN network helps to overcome the overfitting issue, leading a further improved recall rate and precision rate.

scholarly journals Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)

2018 ◽  
Vol 109 (9) ◽  
pp. 2980-2985 ◽  
Author(s):  
Kuniko Sunami ◽  
Hideaki Takahashi ◽  
Katsuya Tsuchihara ◽  
Masayuki Takeda ◽  
Tatsuya Suzuki ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Next Generation Sequencing ◽  
Cancer Diagnosis ◽  
Diagnosis And Treatment ◽  
Next Generation ◽  
Generation Sequencing

Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment

2018 ◽  
pp. 139-146 ◽  
Author(s):  
Howard A. Burris ◽  
Leonard B. Saltz ◽  
Peter P. Yu
Keyword(s):  
Next Generation Sequencing ◽  
Cancer Biology ◽  
Health Care Policy ◽  
Clinical Care ◽  
Dynamic Environment ◽  
Investigational Drug ◽  
Next Generation ◽  
Genomic Alterations ◽  
Clinical Annotation ◽  
Generation Sequencing

Next-generation sequencing (NGS)–based technology has lowered the cost of cancer testing for genomic alterations and is now commercially available from a growing number of diagnostic laboratories. However, laboratories vary in the methodologies underlying their tests, the types and numbers of genomic alterations covered by the test, and the clinical annotation of the sequencing findings. Determining the value of NGS tests is dependent on whether it is used to support clinical trials or as a part of routine clinical care at a time when both the investigational drug pipeline and the list of U.S. Food and Drug Administration–approved or Compendium-listed therapeutics is in a high state of flux. Reimbursement policy for NGS testing by the Centers for Medicare & Medicaid is evolving as the value of NGS testing becomes more clearly defined for specific clinical situations. Patient care and clinical decisions-making are dependent on the oncologist’s knowledge of when NGS testing has value. Here, we review principles and practice for NGS testing in this dynamic confluence of technology, cancer biology, and health care policy.

A Novel Air Purifier for Trace SO2 Removal and Simulation of the Purification Effect

2015 ◽  
Vol 1092-1093 ◽  
pp. 805-809
Author(s):  
Dong Lai Xie ◽  
Jin Hui Luo
Keyword(s):  
Indoor Air ◽  
Large Scale ◽  
Gas Flow ◽  
Test Results ◽  
Confined Space ◽  
Ansys Fluent ◽  
Flow Rates ◽  
The World ◽  
Air Purifier ◽  
Scale Usage

With the large-scale usage of coal and gasoline, China has been the most serious SO2-polluted country in the world. SO2 can cause respiratory and cardiovascular disease, which does great harm to human health. Therefore, developing an air purifier to absorb trace SO2 is very necessary. According to the mechanism of SO2 absorption with the alkaline solution, we developed an air purifier with an purification capacity of 80m3 -100m3 per hour. The purification effect with different gas flow rates, absorbing liquids and initial SO2 concentration was tested. Test results indicated that the purifier had a very good absorption of trace SO2 for indoor air. A SO2 purification model in confined space was established and the purification effect of the purifier was simulated with ANSYS FLUENT 14.0.

Sign in / Sign up

Export Citation Format

Share Document